These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 8287348)

  • 1. Physicians and the pharmaceutical industry (update 1994). Canadian Medical Association.
    CMAJ; 1994 Jan; 150(2):256A-256F. PubMed ID: 8287348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMA issues revised guidelines on physicians' relationship with pharmaceutical industry.
    Williams JR
    CMAJ; 1994 Jan; 150(2):263, 265. PubMed ID: 8287352
    [No Abstract]   [Full Text] [Related]  

  • 3. Approaches to enhancing the quality of drug therapy. A joint statement by the CMA and the Canadian Pharmaceutical Association. Canadian Medical Association.
    CMAJ; 1996 Sep; 155(6):784A-784F. PubMed ID: 8823225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The ANMCO (National Association of Hospital Cardiologists) in a changing health care system. Consensus development of the Organizing Symposium of the XXXI National Congress of Cardiology--ANMCO; Florence, May 21, 2000].
    Ital Heart J Suppl; 2000 Dec; 1(12):1533-44. PubMed ID: 11221582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General Council to consider amendments to CMA policy on MDs' relationships with drug industry.
    Williams JR
    CMAJ; 1993 Aug; 149(3):335-7. PubMed ID: 11659649
    [No Abstract]   [Full Text] [Related]  

  • 6. The physician's relationship with the pharmaceutical industry: caveat emptor...buyer beware!
    Albersheim SG; Golan A
    Isr Med Assoc J; 2011 Jul; 13(7):389-93. PubMed ID: 21838178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed guidelines for housestaff interaction with pharmaceutical companies.
    Forrest DM; Ruedy J
    Ann R Coll Physicians Surg Can; 1993 Oct; 26(5):291-3. PubMed ID: 15362243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMA leads drive to improve physicians' management skills.
    Wharry S
    CMAJ; 1997 Feb; 156(3):409-10. PubMed ID: 9033427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMA guidelines on MD-drug industry relations part of international trend.
    Williams JR
    CMAJ; 1992 Feb; 146(3):386-8. PubMed ID: 11654902
    [No Abstract]   [Full Text] [Related]  

  • 12. Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations.
    Kerridge I; Maguire J; Newby D; McNeill PM; Henry D; Hill S; Day R; Macdonald G; Stokes B; Henderson K
    Intern Med J; 2005 Apr; 35(4):206-10. PubMed ID: 15836497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Canadian Medical Association Code of Ethics 1868 to 1996: a primer for medical educators.
    Brownell AK; Brownell E
    Ann R Coll Physicians Surg Can; 2002 Jun; 35(4):240-243. PubMed ID: 14982086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical responsibilities of physicians in their dealings with pharmaceutical companies.
    Royal College of Physicians and Surgeons of Canada. Biomedical Ethics Committee
    Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):45-8. PubMed ID: 11650305
    [No Abstract]   [Full Text] [Related]  

  • 15. Physicians and the pharmaceutical industry.
    Canadian Medical Association
    CMAJ; 1992 Feb; 146(3):388A-C. PubMed ID: 11654903
    [No Abstract]   [Full Text] [Related]  

  • 16. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers.
    Halperin EC; Hutchison P; Barrier RC
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1477-83. PubMed ID: 15275735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians.
    Brett AS; Burr W; Moloo J
    Arch Intern Med; 2003 Oct; 163(18):2213-8. PubMed ID: 14557219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuing medical education: ethical collaboration between sponsor and industry.
    Wilson FS
    Clin Orthop Relat Res; 2003 Jul; (412):33-7. PubMed ID: 12838049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physicians and the pharmaceutical industry (update 2001).
    Canadian Medical Association
    CMAJ; 2001 May; 164(9):1339-44. PubMed ID: 11341156
    [No Abstract]   [Full Text] [Related]  

  • 20. Gifts to physicians from the pharmaceutical and medical manufacturing industry: what every physician should know.
    Zoorob R; Larzelere M
    J La State Med Soc; 2004; 156(1):28-32. PubMed ID: 15000210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.